COMMUNIQUÉS West-GlobeNewswire

Cartesian Therapeutics Announces New Employment Inducement Grants
07/08/2026
FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
07/08/2026
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May [...]
Treace Medical Concepts Reports Second Quarter 2026 Financial Results
07/08/2026
PONTE VEDRA, Fla., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of [...]
Spectral Medical Announces Second Quarter 2026 Financial Results and Provides Corporate Update
07/08/2026
TORONTO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/08/2026
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
Financière de Tubize - Rapport financier semestriel 2026
07/08/2026
Rapport financier semestriel 2026 Information réglementée - 1 août 2026 Le conseil d’administration de la Financière de Tubize a établi le rapport financier semestriel 2026. Ce rapport est disponible sur le site [...]
Financière de Tubize - 2026 half-year financial report
07/08/2026
Half-year financial report 2026 Regulated information 1 August 2026 The board of directors of Financière de Tubize has established the 2026 half-year report. This report is available on the website www.financiere-tubize [...]
Bavarian Nordic Receives European Commission Approval of Mpox/Smallpox Vaccine for Children Aged 2 to Less than 12 Years
07/08/2026
MVA-BN approval expanded to include children aged 2 to less than 12 years for protection against mpox, smallpox and disease caused by vaccinia virus Approval further strengthens MVA-BN’s position in supporting global [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter 2026
07/08/2026
Tokyo, Japan and Cambridge, UK, 7 August 202 6 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second quarter ended 30 June [...]
National Health Sanitary Association Announces United Nations Procurement and Partnership Registration
07/08/2026
Washington State-based public health organization expands international cooperation framework for disease prevention, health education, humanitarian assistance and community health development. WASHINGTON, Aug. 07, 2026 [...]
Latigo Biotherapeutics Announces Pricing of Upsized $345.6 Million Initial Public Offering
07/08/2026
THOUSAND OAKS, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (“Latigo”), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today announced [...]
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
07/08/2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. , (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop [...]
CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
07/08/2026
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells Lehi Utah, Aug. 06, 2026 [...]
SkinHealth Systems Reports Second Quarter 2026 Financial Results
06/08/2026
LONG BEACH, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (NASDAQ: SKIN) (“SkinHealth Systems” or the "Company"), home to flagship brand Hydrafacial, today announced financial results for the second [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
06/08/2026
CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
06/08/2026
Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK ® ’s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient [...]
Caring Brands Provides Intellectual Property Portfolio Update
06/08/2026
Commercial Patent Portfolio Includes Five Issued U.S. Patents Protecting Core Flagship Platforms Targeting $20B+ Combined Global Dermatology & Hair Care Markets Fort Pierce, FL, Aug. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
06/08/2026
Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1.0 billion to [...]
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
06/08/2026
Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue growth of 27% year-over-year to $31.9 [...]

Pages